Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis

This is a Phase 1/2, open-label study designed to evaluate the safety, tolerability and
procedure of a microneedle injection of triamcinolone acetonide (TA) into the SCS. The
subjects enrolled in this study will be chosen from subjects with non-infectious
intermediate, posterior and pan-uveitis. The injection will only be administered to a single
eye via the Clearside Biomedical proprietary microneedle into the SCS. The dose of TA to be
injected is 4 mg of currently approved TRIESENCE® (triamcinolone acetonide injectable
suspension 40 mg/mL). The study design includes 10 clinic visits over 27 weeks. Subjects
will be followed for 26 weeks following treatment with TRIESENCE®.

Inclusion Criteria:

- diagnosis of non-infectious intermediate, posterior or pan-uveitis

Exclusion Criteria:

- any ocular trauma within the past 6 months in the study eye

- any injection of intraocular corticosteroids or steroid implant or the Ozurdex®
implant in the 6 months prior to the study treatment, or any prior use of Retisert™
in the study eye

- any uncontrolled systemic disease that would preclude participation in the study or
put the subject at risk due to study treatment or procedures

- have a known HIV infection or other immunodeficiency disease for which corticosteroid
therapy would be contraindicated

- are monocular

- have ocular hypertension

- history of any intraocular surgery in the study eye

- presence of an anterior staphyloma in the study eye